Testing an improved chemotherapy prep before stem cell transplant
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a modified chemotherapy “conditioning” plan before an autologous stem cell transplant for people with non-Hodgkin lymphoma. It aims to improve how patients tolerate and recover from the transplant process.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 60 years old, and you can follow the study schedule and return for follow-up.
- You have non-Hodgkin lymphoma and plan to receive your own stem cells (autologous transplant).
- Your general performance is good (ECOG score 0 to 1).
- Your blood counts and organ tests (liver, kidneys, blood clotting, and heart tests) must be within allowed ranges.
- If you can get pregnant: your pregnancy test is negative and you will use highly effective birth control during the study.
- You should not have certain heart problems or recent serious heart/heart rhythm issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study compares two chemotherapy schedules (Chi-BEAM vs BEAM) given before an autologous stem cell transplant to treat newly diagnosed peripheral T-cell lymphoma that responded to first-line treatment. If you fit the lab and heart/lung requirements, it may offer access to a new treatment approach designed to improve outcomes.
This trial tests a combination of four chemotherapy drugs (mitoxantrone liposome, bendamustine, etoposide, and cytarabine) given before a stem cell transplant for people with lymphoma. The goal is to prepare the body for the transplant and improve outcomes.
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to the standard BEAM chemotherapy before a stem cell transplant can help people with relapsed Hodgkin lymphoma. It's for patients who are eligible for a transplant and have stable organ function.
This trial tests a risk-adapted conditioning regimen (chemotherapy and/or radiation given before transplant) for people with certain blood cancers or bone marrow disorders who need a stem cell transplant from a donor. The goal is to tailor the conditioning strength to each patient’s risk, which may help improve outcomes and reduce side effects.
This trial tests a combination of drugs (thiotepa, cyclophosphamide, clarithromycin, and cytarabine) before a stem cell transplant. It is for people with certain types of blood cancer who have responded well to earlier treatment.
This trial tests a stronger chemotherapy and radiation regimen before a donor stem cell transplant for people with acute myeloid leukemia or high-risk myelodysplastic syndrome. The goal is to eliminate any remaining cancer cells and improve transplant success.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.